Optimizing generalizability of biomarker studies for Alzheimer’s disease and related dementias with epidemiologic tools
Optimizing generalizability of biomarker studies for Alzheimer’s disease and related dementias with epidemiologic tools
批准号:
10359225
负责人:
Elizabeth Rose Mayeda
金额:
$58.25万
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
已结题
起止时间:
2021-05-01 至 2024-04-30
关键词:
Alzheimer&aposs DiseaseAlzheimer&aposs disease related dementiaAlzheimer’s disease biomarkerAmyloidBiologicalBiological MarkersBrainCognitiveConfidence IntervalsDataData Coordinating CenterDementiaDiseaseEpidemiologyFutureGeneral PopulationGenetic RiskGenotypeGoalsHealthImpaired cognitionInvestmentsLifeLife ExperienceMagnetic Resonance ImagingMeasuresMemory LossOutcomeParticipantPopulationPositron-Emission TomographyPrevalenceProcessRaceResearchResearch DesignResearch PersonnelRisk FactorsSamplingSampling StudiesStructureSymptomsUncertaintyWeightWorkanalytical methodanalytical toolapolipoprotein E-4basecardiometabolismcognitive changecohortdementia riskdepressive symptomsdesignhealthy agingimprovedinterestmagnetic resonance imaging biomarkermild cognitive impairmentneuroimagingnovel markerpre-clinicalpreventrecruitsociodemographic groupsociodemographicstau Proteinstooluser-friendly
中文摘要
项目总结
英文摘要
PROJECT SUMMARY
Characterizing the biological mechanisms of Alzheimer's disease and related dementias (ADRD) is crucial for
identifying effective strategies to prevent and treat dementia. Careful and substantial investments have
enabled characterization of preclinical Alzheimer's disease (AD) using the AT(N) framework based on
biomarkers, but the limited diversity of biomarker study samples may limit generalizability of findings from
these studies. Unfortunately, early attempts to increase diversity have not solved the problem of non-
generalizable study results due to differential selection processes across sociodemographic groups. Thus,
increasing diversity of study samples is necessary, but not sufficient, for achieving generalizable study results.
Our overall objective is to develop tools and approaches to enhance the generalizability of ADRD biomarker
studies. It is increasingly recognized that evaluating generalizability of ADRD study results is important, but
researchers are stymied by lack of tools for systematically evaluating generalizability of findings. Standard
analytic methods do not take full advantage of currently available data and do not reveal the extent of
uncertainty in estimates when generalizing to the entire population. New epidemiologic and statistical tools,
including weighting and g-computation (“transport tools”), allow for generalizing results from a study to an
external population of interest. We propose to apply transport tools to develop population-level estimates of the
predictive accuracy of ADRD AT(N) biomarkers on cognitive outcomes and prevalence of preclinical AD (Aim
1) and effects of risk factors on ADRD AT(N) biomarkers (Aim 2) using data from Alzheimer's Disease
Neuroimaging Initiative (ADNI), the French MEMENTO cohort, and Kaiser Healthy Aging and Diverse Life
Experiences (KHANDLE) and Life After 90 (LA90), two newly available, exceptionally diverse ADRD biomarker
samples with harmonized measures. Generalizing from a study sample to a population always increases
uncertainty in estimated effects relative to estimates in the sample (e.g. wider confidence intervals and reduced
power), but the magnitude of added uncertainty due to generalizing depends on the composition of the sample.
Currently, there are no tools to evaluate how the composition of a proposed study will impact statistical power
to detect population-representative effects (i.e. draw generalizable inferences from the proposed study). In Aim
3, we will develop a power calculator for population-level estimates based on the sociodemographic
composition of the proposed sample, enabling researchers to evaluate generalizability in the study design
stage. This project advances critical analytic tools to improve generalizability of existing ADRD biomarker
studies, which can be applied to novel biomarkers and help prioritize recruitment goals. Developing transport
tools for ADRD biomarker research will help researchers obtain the best possible evidence on how to prevent
and effectively treat ADRD in the entire population.
期刊论文(3)
专著(0)
科研奖励(0)
会议论文
Alzheimer's disease and related dementias in a diverse cohort of Asian Americans
-
批准号:10407959
-
项目类别:
-
资助金额:$49.87万
-
财政年份:2019
-
负责人:Elizabeth Rose Mayeda
-
依托单位:
Alzheimer's disease and related dementias in a diverse cohort of Asian Americans
-
批准号:10000819
-
项目类别:
-
资助金额:$46.86万
-
财政年份:2019
-
负责人:Elizabeth Rose Mayeda
-
依托单位:
Racial Disparities in Alzheimer's Disease and Related Dementias: The Role of Blood Pressure Throughout Adulthood
-
批准号:9164027
-
项目类别:
-
资助金额:$12.63万
-
财政年份:2016
-
负责人:Elizabeth Rose Mayeda
-
依托单位:
Racial Disparities in Alzheimer's Disease and Related Dementias: The Role of Blood Pressure Throughout Adulthood
-
批准号:9899176
-
项目类别:
-
资助金额:$22.4万
-
财政年份:2016
-
负责人:Elizabeth Rose Mayeda
-
依托单位:
国内基金
海外基金
新型F-18标记香豆素衍生物PET探针的研制及靶向Alzheimer's Disease 斑块显像研究
-
批准号:81000622
-
项目类别:青年科学基金项目
-
资助金额:20.0万元
-
批准年份:2010
-
负责人:梁胜
-
依托单位:
阿尔茨海默病(Alzheimer's disease,AD)动物模型构建的分子机理研究
-
批准号:31060293
-
项目类别:地区科学基金项目
-
资助金额:26.0万元
-
批准年份:2010
-
负责人:郭亚芬
-
依托单位:
跨膜转运蛋白21(TMP21)对引起阿尔茨海默病(Alzheimer'S Disease)的γ分泌酶的作用研究
-
批准号:30960334
-
项目类别:地区科学基金项目
-
资助金额:22.0万元
-
批准年份:2009
-
负责人:董贵成
-
依托单位: